Hormonal therapies frequently fail and patients may relapse with ‘castrate-resistant’ prostate cancer.2, 3, 4 Resistance results from clonal selection of cells that circumvent androgen requirement by mechanisms including AR mutation, amplification or changes in AR cofactor (coactivator and corepressor) levels. This evidence concerns the gene AR and prostate cancer.